Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

MLA

Ye, Xing-Nong, et al. “Epigenetic Priming with Decitabine Followed by Low-Dose Idarubicin/Cytarabine Has an Increased Anti-Leukemic Effect Compared to Traditional Chemotherapy in High-Risk Myeloid Neoplasms.” Leukemia & Lymphoma, vol. 57, no. 6, June 2016, pp. 1311–18. EBSCOhost, https://doi.org/10.3109/10428194.2015.1091931.

APA

Ye, X.-N., Zhou, X.-P., Wei, J.-Y., Xu, G.-X., Li, Y., Mao, L.-P., Huang, J., Ren, Y.-L., Mei, C., Wang, J.-H., Lou, Y.-J., Ma, L.-Y., Yu, W.-J., Ye, L., Xie, L.-L., Luo, Y.-W., Hu, C., Niu, L.-M., Dou, M.-H., & Jin, J. (2016). Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. Leukemia & Lymphoma, 57(6), 1311–1318. https://doi.org/10.3109/10428194.2015.1091931

Chicago

Ye, Xing-Nong, Xin-Ping Zhou, Ju-Ying Wei, Gai-Xiang Xu, Ying Li, Li-Ping Mao, Jian Huang, et al. 2016. “Epigenetic Priming with Decitabine Followed by Low-Dose Idarubicin/Cytarabine Has an Increased Anti-Leukemic Effect Compared to Traditional Chemotherapy in High-Risk Myeloid Neoplasms.” Leukemia & Lymphoma 57 (6): 1311–18. doi:10.3109/10428194.2015.1091931.